Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
Kyverna Therapeutics to Present at Upcoming Investor Conferences
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA
Kyverna Therapeutics: 'Strong Buy' On Additional POC Of Miv-Cel In Myasthenia Gravis
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
Kyverna Therapeutics Positive Phase 2 Readout: Deep Responses, But Very Small Sample
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $28.67 Average Price Target from Analysts
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Brokerages Set Kyverna Therapeutics, Inc. (NASDAQ:KYTX) PT at $28.67
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026
Kyverna Therapeutics to Participate in Upcoming March Investor Conferences
Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors
Wall Street Thinks These 4 Biotech Stocks Will Double–At Least–This Year
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference
Kyverna Therapeutics Stock Up 41% in a Month: Here's Why
Kyverna Therapeutics: Taking The Next Step In Autoimmune Cell Therapies
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome Transcript
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock
Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study Data
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Traders Buy High Volume of Kyverna Therapeutics Call Options (NASDAQ:KYTX)
Stock Market Today, Dec. 15: U.S Stocks Ease as Investors Wait for Rate Clarity
Kyverna Therapeutics Announces Proposed Public Offering of Common Stock
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome
Kyverna's cell therapy meets main goal of mid-stage study
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome
Stock Picks From Seeking Alpha's November 2025 New Analysts
Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores Potential
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Kyverna Therapeutics to Present at the Jefferies London Healthcare Conference
Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance
Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025
Kyverna Therapeutics Highlights Potential of KYV-101 in Rheumatoid Arthritis with Phase 1 Data from Investigator-Initiated Trial Presented at ACR Convergence 2025
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
KYVERNA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation Into Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
Kyverna Therapeutics Highlights Neuroimmunology CAR T Franchise and Registrational Phase 3 Trial Design in Myasthenia Gravis at Virtual KOL Event